Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

taneous coronary interventions. Circulation 2001;104:263–268. 5. Malenka D, O’Rourke D, Miller M, Hearne M, Shubrooks S, Kellett MJ, Robb J, O’Meara J, VerLee P, Bradley W, et al. Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty. The Northern New England Cardiovascular Disease Study Group. Am Heart J 1999;137:632–638. 6. O’Connor G, Malenka D, Quinton H, Robb J, Kellett MJ, Shubrooks S, Bradley W, Hearne M, Watkins M, Wennberg D, et al. Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994-1996. J Am Coll Cardiol 1999;34:581–591. 7. Kimmel S, Berlin J, Strom B, Laskey W. Development and validation of simplified predictive index for major complications in contemporary percutaneous transluminal coronary angioplasty practice. The registry committee of the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1995;26: 931–938. 8. Webb J. Interventional management of cardiogenic shock. Can J Cardiol 1998;14:233–244. 9. Webb J, Sanborn T, Sleeper L, Carere R, Buller C, Slater J, Baran K, Koller P, Talley J, Porway M, Hochman J. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J 2001;141:964 – 970.